JP Patent

JP7383676B2 — カリクレインインヒビターとしての、ｎ－［（３－フルオロ－４－メトキシピリジン－２－イル）メチル］－３－（メトキシメチル）－１－（｛４－［（２－オキソピリジン－１－イル）メチル］フェニル｝メチル）ピラゾール－４－カルボキサミドの多形体

Assigned to カルビスタ・ファーマシューティカルズ・リミテッド · Expires 2023-11-20 · 2y expired

What this patent protects

Patent listed against Ekterly.

Drugs covered by this patent

Patent Metadata

Patent number
JP7383676B2
Jurisdiction
JP
Classification
—
Expires
2023-11-20
Drug substance claim
No
Drug product claim
No
Assignee
カルビスタ・ファーマシューティカルズ・リミテッド
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.